Answers are grounded in this paper and cite their sources.
Articular cartilage injury and degeneration pose a major global health challenge, often leading to irreversible function loss and the development of osteoarthritis. Clinical therapies focus on relieving symptoms, underscoring the need to develop innovative treatment strategies capable of achieving genuine cartilage regeneration. In recent years, breakthrough approaches in regenerative medicine based on cell reprogramming have brought promise for this field. In this review, we synthesize and critically analyze the latest advances in cell reprogramming for cartilage regeneration, with a focus on the derivation of induced pluripotent stem cells (iPSCs), direct lineage reprogramming, genome‐editing tools such as clustered regularly interspaced short palindromic repeats‐associated protein 9 (CRISPR‐Cas9), and the regulatory roles of microRNAs (miRNAs) and small molecules. We also emphasize the role of biomaterial scaffolds as key platforms for cell delivery and microenvironmental modulation, detailing their compositional optimization and functional modifications that may enhance reprogramming efficiency, directed differentiation, and transplantation outcomes. Finally, we comment on the core challenges of clinical translation, including technical and biological barriers, scalable manufacturing, and long‐term efficacy. Looking ahead, refining reprogramming techniques, exploring emerging technologies, and conducting rigorous preclinical and clinical studies will be key steps to enabling the successful application of cell reprogramming therapies in cartilage regeneration.
No takes yet. Share an insight, caveat, or question.
Assadi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: